Clinical Trial Update: Randomized Trial of Crenolanib in Subjects With D842V Mutated GIST [Phase 3]

View source ↗

Summary

A randomized Phase 3 trial evaluating crenolanib in GIST patients with the D842V PDGFRA mutation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumor
• Pdgfra-mutant Gastrointestinal Stromal Tumor

Drugs mentioned

• Crenolanib (Crenolanib)

Snippet

Sponsor: Arog Pharmaceuticals, Inc. | Conditions: GIST With D842V Mutated PDGFRA Gene | Phase 3 | Status: UNKNOWN